sr 140333 has been researched along with Colorectal Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, Y; Cheng, X; Fu, C; Hong, X; Kang, J; Ma, J; Meng, Y; Shao, G; Shi, Y; Wang, L; Wang, X; Wang, Y; Yan, Z; Zhang, Q | 1 |
1 other study(ies) available for sr 140333 and Colorectal Cancer
| Article | Year |
|---|---|
A Novel Mechanism of Endoplasmic Reticulum Stress- and c-Myc-Degradation-Mediated Therapeutic Benefits of Antineurokinin-1 Receptor Drugs in Colorectal Cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aprepitant; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Extracellular Signal-Regulated MAP Kinases; Humans; Mice; Mice, Nude; Neurokinin-1 Receptor Antagonists; Piperidines; Proto-Oncogene Proteins c-myc; Quinuclidines; Signal Transduction; Survival Rate; Transplantation, Heterologous | 2021 |